Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8<sup>+</sup> T cells and inhibited tumor growth
Our data demonstrates the potential of activating TNFRSF25 by Abs and multimeric TL1A proteins for cancer immunotherapy and provides insights into their development astherapeutics.
Authors
- Jianhua Sui (ORCID: https://orcid.org/0000-0002-1272-9662)
- Xueyuan Lyu (ORCID: https://orcid.org/0009-0008-4870-8354)
- Yulu Li (ORCID: https://orcid.org/0000-0001-6516-344X)
- Linlin Zhao (ORCID: https://orcid.org/0000-0003-4827-023X)
- Yajing Yang (ORCID: https://orcid.org/0009-0006-6950-142X)
- Huisi Liu
- Wenhui Li (ORCID: https://orcid.org/0000-0003-1305-7404)
- Sijia Chen (ORCID: https://orcid.org/0000-0002-8464-5003)
- Fang Yang (ORCID: https://orcid.org/0009-0006-9446-5117)
Institutions
- Peking University (CN)
- National Institute of Biological Sciences, Beijing (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1136/jitc-2024-008810
- Citations
- 5
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.20
Funders
- Tsinghua University
- Beijing Municipal Science and Technology Commission